Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.46 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533481 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTMEN1KMT2AFFAR2 | |
| SCHEMBL3535758 | 0.78 | SMN1; SMN2 (0.40) | SMN1; SMN2HTTMEN1KMT2AFFAR2 | |
| SCHEMBL1585075 | 0.78 | BRD4 (0.43) | BRD4RAB9ALRRK2MARK3FLT3 | |
| SCHEMBL2540233 | 0.78 | BRD4 (0.51) | SMN1; SMN2HTTMEN1KMT2AHTR6 | |
| SCHEMBL1585008 | 0.78 | BRD4 (0.43) | HTTMEN1KMT2AHTR6LMNA | |
| SCHEMBL2600002 | 0.77 | FFAR2 (0.43) | FFAR2HTR6BRD4ALDH1A1 | |
| SCHEMBL2547183 | 0.76 | BRD4 (0.43) | FFAR2HTR6BRD4 | |
| SCHEMBL2110804 | 0.75 | BRD4 (0.43) | MEN1KMT2AHTR6BRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2794514 | 0.74 | HTR6 (0.50) | MEN1KMT2AHTR6RECQL | |
| SCHEMBL30295279 | 0.71 | MEN1 (0.44) | MEN1KMT2ARAB9AKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050090496-A1 | Sulphonyl compounds with 5-ht6 receptor affinity | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090496-A1 | Sulphonyl compounds with 5-ht6 receptor affinity | HTR6, HTR4, HTR5A | SMN1; SMN2 862/4885HTT 373/4885MEN1 3904/4885 |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | SMN1; SMN2 3484/4885HTT 4247/4885MEN1 1878/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | SMN1; SMN2 3484/4885HTT 4247/4885MEN1 1878/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | SMN1; SMN2 3594/4885HTT 4169/4885MEN1 1601/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | SMN1; SMN2 3484/4885HTT 4247/4885MEN1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.